Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

67.75 -1.47 (-2.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,834,959
Open 68.07
Bid (Size) 67.74 (41)
Ask (Size) 67.75 (2)
Prev. Close 69.22
Today's Range 67.56 - 68.96
52wk Range 53.56 - 83.95
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire

Performance

YTD
-2.6%
-2.6%
1 Month
+10.8%
+10.8%
3 Month
-0.2%
-0.2%
6 Month
-1.2%
-1.2%
1 Year
+8.1%
+8.1%

More News

Read More
Where Incyte Stands With Analysts
Via Benzinga
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
From Incyte
Via Business Wire
Earnings Scheduled For April 29, 2025
Via Benzinga
INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech
Via Chartmill
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
What's going on in today's session: S&P500 movers
Via Chartmill
3 Mid-Cap Stocks with Questionable Fundamentals
Via StockStory
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
From Incyte
Via Business Wire
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
Via StockStory
Topics World Trade
Exposures Tariff
These S&P500 stocks that are showing activity before the opening bell on Thursday.
Via Chartmill
INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals.
Via Chartmill
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
INCYTE CORP (NASDAQ:INCY) – A Look at Its Dividend Potential
Via Chartmill
9 Analysts Have This To Say About Incyte
Via Benzinga
Discover the top S&P500 movers in Tuesday's after-hours session.
Via Chartmill
Tuesday's pre-market session: top gainers and losers in the S&P500 index
Via Chartmill
3 Value Stocks Facing Headwinds
Via StockStory
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?
Via Benzinga
Topics Bonds
Exposures Debt Markets
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers
Via StockStory
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Incyte (INCY) Q1 Earnings Report Preview: What To Look For
Via StockStory
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
From Incyte
Via Business Wire

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 67.75
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 06/13/25 04:00 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 15.07B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.